Dediabetes Logo
Questions
Published answers connected to evidence
Clinical Reference
Detailed intervention and outcome dossiers
Latest Research
Newest studies
About
How deDiabetes works
Settings
Login / Sign-up
Research Summary
Analyzed using Evidence Intelligence™

Exenatide improves glucose control in type 2 diabetes

Powered by the Dediabetes Evidence Intelligence™ framework

Last updated September 12, 2026

Key finding

Once-weekly exenatide significantly reduced 24-hour mean glucose level versus placebo (week 4, -1.44 vs -0.29 mmol/L).

Once-weekly exenatide significantly improved glycaemic control in adults with type 2 diabetes compared to placebo.

Quick read

Study at a glance

The essential study design details in one scan.

EvidenceScore™

Moderate

Study type

RCTs

Follow-up

Short-Term (≤3 mo)

Risk of bias

Some Concerns

Save research, organize studies, and quickly find important evidence again.

Plain-language summary

What this paper says

A plain-language read of the study’s main message and where it applies.

Study focus

Once-weekly exenatide significantly improved glycaemic control in adults with type 2 diabetes compared to placebo.

Clinical relevance

These findings are significant as they suggest that once-weekly exenatide can be an effective treatment option for adults with type 2 diabetes, helping to manage blood sugar levels more effectively. Improved glycaemic control can lead to better long-term health outcomes and reduce the risk of diabetes-related complications, making it a valuable addition to diabetes management strategies.

Keep in mind

The study's sample size and demographic diversity may limit generalizability. Potential bias from self-reported outcomes could affect accuracy. Short duration of the trial may not capture long-term effects.

Published in

Journal Reference

Publication details and source links for this paper.

Juan PF, Samer N, James AR, et al. Once-Weekly Exenatide Improves Glycaemic Control and Reduces Variability in Adults with Type 2 Diabetes. Diabetes, Obesity & Metabolism. 2016;19(1):40-48. doi:10.1111/dom.12763

View DOIView on PubMedView on PMC

Main Effects

Once-weekly exenatide reduced 24-hour mean glucose by -1.44 mmol/L at week 4 and -1.71 mmol/L at week 10.

Fasting plasma glucose decreased by -1.65 mmol/L at week 4 and -2.32 mmol/L at week 10 with exenatide.

Participants on exenatide spent 77% of the time in euglycaemia compared to 58% in the placebo group.

Evidence network

How this study fits

Understand where this research contributes within the broader evidence network.

Evidence Context

This study contributes evidence to Exenatide and 2-hour plasma glucose, Fasting Plasma Glucose (FPG), Gastrointestinal disorders incidence, and 7 more.

This study contributes evidence to

Intervention

Exenatide

Outcome

2-hour plasma glucose

Evidence topic

Glycemic Control

Primary intervention

Exenatide

Primary outcomes

  • 2-hour plasma glucose
  • Fasting Plasma Glucose (FPG)
  • Gastrointestinal disorders incidence

Evidence topics

Glycemic ControlPost-Meal and OGTT GlucoseFasting Blood GlucoseGlucose Variability

Primary intervention

Exenatide

Primary outcomes

2-hour plasma glucoseFasting Plasma Glucose (FPG)Gastrointestinal disorders incidence

Evidence relationships

Intervention and outcome relationships this study adds to the evidence network.

10
Evidence pairs
10
Relationships
5
Evidence topics
contributes_evidence

Editorial context

Why this study matters

See why this paper is useful beyond its individual results.

Evidence network role

This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.

Moderate contributionModerate confidenceNetwork score: 68

5

Related topics

10

Evidence pairs

1177

Related studies

High relevance in at least one topic

Why it is useful

  • Contributes to 10 evidence relationships
  • Includes primary outcome data
  • Linked to 5 direct semantic evidence topics

Topic contributions

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Add related evidence to your Evidence Tracker

Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.

Primary evidence

Evidence relationship

GLP-1 Receptor Agonists and Fasting Glucose

Related evidence

Evidence relationship

GLP-1 Receptor Agonists and Postprandial and OGTT Glucose

Save evidence

Evidence relationship

GLP-1 Receptor Agonists and Gastrointestinal Adverse Events

Save evidence

Core evidence

Study findings

The primary outcomes reported in this study.

2-hour plasma glucose

Exenatide → 2-hour plasma glucose

Exenatide → 2-hour plasma glucose

Evidence Intelligence™
EvidenceScore™
Emerging
Score 59 · Based on 1 study
ImpactScore™
100
Very Positive
ConsistencyScore™
unclear
Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence Tracker

Fasting Plasma Glucose (FPG)

Exenatide → Fasting Plasma Glucose (FPG)

Exenatide → Fasting Plasma Glucose (FPG)

Evidence Intelligence™
EvidenceScore™
Strong
Score 79 · Based on 3 studies
ImpactScore™
100
Very Positive
ConsistencyScore™
100
consistent
Supporting studies: Based on 3 studies
Add to Evidence Tracker

Gastrointestinal disorders incidence

Exenatide → Gastrointestinal disorders incidence

Exenatide → Gastrointestinal disorders incidence

Evidence Intelligence™
EvidenceScore™
Emerging
Score 59 · Based on 1 study
ImpactScore™
50
Neutral
ConsistencyScore™
unclear
Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence Tracker

Increase in time spent in euglycemia

Exenatide → Increase in time spent in euglycemia

Exenatide → Increase in time spent in euglycemia

Evidence Intelligence™
EvidenceScore™
Emerging
Score 59 · Based on 1 study
ImpactScore™
100
Very Positive
ConsistencyScore™
unclear
Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence Tracker

Injection-site nodule

Exenatide → Injection-site nodule

Exenatide → Injection-site nodule

Evidence Intelligence™
EvidenceScore™
Emerging
Score 59 · Based on 1 study
ImpactScore™
50
Neutral
ConsistencyScore™
unclear
Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence Tracker

Mean amplitude of glycemic excursions (MAGE)

Exenatide → Mean amplitude of glycemic excursions (MAGE)

Exenatide → Mean amplitude of glycemic excursions (MAGE)

Evidence Intelligence™
EvidenceScore™
Moderate
Score 69 · Based on 2 studies
ImpactScore™
100
Very Positive
ConsistencyScore™
100
consistent
Supporting studies: Based on 2 studies
Add to Evidence Tracker

Postprandial blood glucose

Exenatide → Postprandial blood glucose

Exenatide → Postprandial blood glucose

Evidence Intelligence™
EvidenceScore™
Emerging
Score 59 · Based on 1 study
ImpactScore™
100
Very Positive
ConsistencyScore™
unclear
Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence Tracker

Standard deviation of glucose

Exenatide → Standard deviation of glucose

Exenatide → Standard deviation of glucose

Evidence Intelligence™
EvidenceScore™
Moderate
Score 69 · Based on 2 studies
ImpactScore™
100
Very Positive
ConsistencyScore™
100
consistent
Supporting studies: Based on 2 studies
Add to Evidence Tracker

Time spent in hyperglycaemic range

Exenatide → Time spent in hyperglycaemic range

Exenatide → Time spent in hyperglycaemic range

Evidence Intelligence™
EvidenceScore™
Emerging
Score 59 · Based on 1 study
ImpactScore™
100
Very Positive
ConsistencyScore™
unclear
Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence Tracker

Urinary tract infection rate

Exenatide → Urinary tract infection rate

Exenatide → Urinary tract infection rate

Evidence Intelligence™
EvidenceScore™
Emerging
Score 59 · Based on 1 study
ImpactScore™
50
Neutral
ConsistencyScore™
unclear
Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence Tracker

Evidence Library

Build your evidence library

Save research, organize studies, and quickly find important evidence again.

evidence suggest

Evidence Suggest

  • Exenatide reduced 2-hour postprandial glucose by -1.79 mmol/L at week 4.
  • MAGE was reduced by -0.84 mmol/L at week 10 with exenatide.
  • Time spent in hyperglycaemia decreased to 22% in the exenatide group.
who this applies

Who this applies to

  • Adults aged 18-75 with type 2 diabetes.
  • Participants who are inadequately controlled on current diabetes medications.
keep in mind

Keep in Mind

  • Results may not apply to populations outside the study's demographic.
  • Further research is needed to assess long-term safety and efficacy.
  • Adverse events reported were generally mild but should be monitored.
between the lines

Between the Lines

  • The study's sample size and demographic diversity may limit generalizability.
  • Potential bias from self-reported outcomes could affect accuracy.
  • Short duration of the trial may not capture long-term effects.

Evidence Library

Build your evidence library

Save research, organize studies, and quickly find important evidence again.

Connected Evidence

Explore related studies, evidence collections, and research questions.

Relationships organized using the Dediabetes Evidence Intelligence™ framework.

Powered by the Dediabetes Evidence Intelligence™ framework

This study contributes to evidence on GLP-1 Receptor Agonists and Fasting Glucose, GLP-1 Receptor Agonists and Glucose Variability.

Related evidence relationships

Explore in Evidence Explorer

This study contributes to the evidence on the following intervention-outcome relationships.

Questions answered by this study

Generated from the study's connected evidence using Evidence Intelligence™.

Do GLP-1 Receptor Agonists improve fasting glucose?

Strong Evidence

GLP-1 Receptor Agonists may improve fasting glucose.

ConsistencyScore™: Results are generally consistent across studies.

Ranked evidence signals

  1. 1

    Fasting Plasma Glucose (FPG)

    EvidenceScore™ Strong | EvidenceScore™ 79.0 | strong positive | ConsistencyScore™ Consistent | 1 study

Why this answer: This answer is based on 18 supporting studies with generally consistent results and a positive effect signal.

18 supporting studies
View Full Evidence

Do GLP-1 Receptor Agonists improve postprandial and ogtt glucose?

Strong Evidence

GLP-1 Receptor Agonists may improve postprandial and ogtt glucose.

ConsistencyScore™: Results are consistent across studies.

Ranked evidence signals

  1. 1

    2-hour plasma glucose

    EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study

  2. 2

    Postprandial blood glucose

    EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on 10 supporting studies with consistent results and a positive effect signal.

10 supporting studies
View Full Evidence

Do GLP-1 Receptor Agonists affect gastrointestinal adverse events?

Strong Evidence

Current evidence does not show a clear effect of GLP-1 Receptor Agonists on gastrointestinal adverse events.

ConsistencyScore™: Results are consistent across studies.

Ranked evidence signals

  1. 1

    Gastrointestinal disorders incidence

    EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on 12 supporting studies and existing graph evidence signals.

12 supporting studies
View Full Evidence

Do GLP-1 Receptor Agonists improve glucose variability?

Strong Evidence

GLP-1 Receptor Agonists may improve glucose variability.

ConsistencyScore™: Results are consistent across studies.

Ranked evidence signals

  1. 1

    Mean amplitude of glycemic excursions (MAGE)

    EvidenceScore™ Moderate | EvidenceScore™ 69.0 | strong positive | ConsistencyScore™ Consistent | 1 study

Why this answer: This answer is based on 4 supporting studies with consistent results and a positive effect signal.

4 supporting studies
View Full Evidence
Learn how Evidence Intelligence™ works

Next steps

Continue your research

Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.

Evidence topics

Follow the topics this study contributes to.

Glycemic Control Evidence HubPost-Meal and OGTT Glucose Evidence HubFasting Blood Glucose Evidence HubGlucose Variability Evidence Hub

Explore in Evidence Explorer

Open broader Evidence Explorer views for this relationship.

All studies on Exenatide and 2-hour plasma glucoseAll studies on Exenatide and Fasting Plasma Glucose (FPG)All studies on Exenatide and Mean amplitude of glycemic excursions (MAGE)All studies on Exenatide and Standard deviation of glucose

Related research

Read related research summaries.

Exenatide does not affect renal function in type 2 diabetesExenatide improves glycemic control and reduces weight in T2DM patientsBaseline features predict exenatide efficacy in type 2 diabetesNutritional Therapy and AGIs Improve Postprandial Glucose in DiabetesAerobic and resistance exercise improve blood glucose control in pre-diabetes

No ads. No tracking.

Focused on evidence, not advertising.

Secure & private

Your data is always protected.

Always up to date

New studies added every day.